Marksans Pharma Ltd

Marksans Pharma | 524404

Live

₹272.40

₹4.91 (-1.77%)

As on 10/07/26, 7:15 PM

Market Cap12,566.23 CR

Current Price₹272.4

High / Low₹281.6 / 155

PE Ratio26.47

Book Value₹54.44

Dividend Yield0.36%

ROCE20.19%

ROE14.45%

Face Value₹2.00

Current Vol.21,92,697

Average Vol.---

ISININE750C01026

PB Ratio4.08

Debt to Equity0.12

Net Profit Margin14.59

Operating Margin22.84

Share Price Chart - Marksans Pharma Ltd

+₹0.00 (+0.00%)6M

Stock Performance

₹277.3₹279.5

₹272.4

Previous CloseToday's Open

₹155₹281.6

₹272.4

52W Low52W High

₹279.5Today's Open

₹277.3Previous Close

21,92,697Volume

₹15552W Low

₹281.652W High

Ratios

No data available

About Company

Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982
Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005
The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation
The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai
In 2004-05, the Company amalgamated with M/s
Marksans Pharma Limited (formerly M/s
Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005
As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s
Marksans Pharma Limited (formerly M/s
Glenmark Laboratories Limited)

Ethics: Marksans Pharma Ltd is flagged for

Animal Cruelty

The company engages directly in some form of animal cruelty through its business.

Below average

---

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI66.65

SMA 20260.72

SMA 50234.73

SMA 100204.62

SMA 200192.17

SMA 10265.44

MACD_12_26_Days9.27

EMA10Day265.17

EMA20Day259.11

EMA50Day238.49

MACD_12_26_9_Days-0.99

EMA100Day218.69

EMA200Day208.74

Pivot Points

Volume Analysis

Delivery

Total Volume

Growth Rate

Revenue Growth20.46%

ROE16.89%

EBITDA Margin22.84%

All figures in ₹ Crores

Indicators	2025	2024	2023	2022	2021
Revenue	2,622.85	2,177.41	1,852.14	1,490.84	1,376.18
Interest	11.66	11.20	9.13	8.45	7.99
Expenses	2,094.21	1,718.83	1,512.82	1,231.96	1,036.57
Financing Profit	599.01	509.00	398.63	300.73	346.30
Financing Margin %	23%	23%	22%	20%	25%
Other Income	70.38	50.42	59.31	41.85	6.69
Depreciation	83.39	74.27	51.85	44.78	36.15
Profit before tax	503.97	423.53	337.65	247.51	302.16
Tax %	24%	26%	21%	25%	21%
Net Profit	382.62	314.90	265.32	186.81	238.54
EPS in Rs	8.40	6.92	6.41	4.51	5.76

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

Deal	Date	Type	Quantity	Price	Traded %
UNIFI CAPITAL PRIVATE LIMITED -BLENDED RANGOLI	11 Jun ‘25	Purchase	32,47,600	₹249.95	83.40%
UTI MUTUAL FUND	11 Jun ‘25	Purchase	4,14,093	₹249.95	10.63%
UNIFI CAPITAL PRIVATE LIMITED	11 Jun ‘25	Purchase	5,94,000	₹249.95	15.25%
UNIFI BLEND FUND 2	11 Jun ‘25	Purchase	30,00,000	₹249.95	77.04%
UNIFI BCAD FUND	11 Jun ‘25	Purchase	5,60,000	₹249.95	14.38%
SOCIETE GENERALE	11 Jun ‘25	Purchase	9,20,184	₹249.95	23.63%
CITIGROUP GLOBAL MARKETS SINGAPORE PTE LIMITED	11 Jun ‘25	Purchase	4,00,081	₹249.95	10.27%
BANDHAN MUTUAL FUND	11 Jun ‘25	Purchase	6,00,000	₹249.95	15.41%
SUBHKAM VENTURES I PRIVATE LIMITED	11 Jun ‘25	Purchase	5,37,485	₹249.95	13.80%
ORBIMED ASIA IV MAURITIUS FVCI LIMITED	11 Jun ‘25	Sell	1,02,73,443	₹249.95	263.83%

News

08 Jul 2026 12:00 am

Marksans Pharma inks deal to acquire ABCnow GmbH

08 Jul 2026 12:00 am

Marksans Pharma rises after acquiring 100% stake in ABCnow GmbH

Record Date

Corporate Action

Information

Announcement Day

08 Aug 2025

AGM

11 Jul 2025

01 Aug 2025

Final Dividend (₹0.8)

Recommended a final dividend of Rs. 0.80 per Equity Share (face value Re. 1 per share) for the financial year 2024-25. The dividend, if approved by the Members at the forthcoming Annual General Meeting ('AGM') will be credited / dispatched within 30 days from the date of AGM he Company has fixed Friday, August 01, 2025 as the Record Date for determining eligibility of Members to receive final dividend for the financial year ended March 31, 2025. The Board, at its meeting held on May 19, 2025, has recommended a final dividend of ? 0.80/- (80%) per equity share of face value of ? 1/- each for the financial year ended March 31, 2025, subject to approval of Members of the Company at the ensuing AGM. (As Per BSE Announcement Dated on 11.07.2025)

19 May 2025

24 Sept 2024

AGM

19 Aug 2024

17 Sept 2024

Final Dividend (₹0.6)

The Board has approved final dividend of Rs. 0.60 per equity share

30 May 2024

28 Aug 2023

AGM

02 Aug 2023

07 Jun 2023

Final Dividend (₹0.5)

Declaration of dividend @ Re. 0.50 (Rupee Zero and Paise Fifty) i.e. 50% per equity share ofRe. 1/- each face value for the financial year 2022-23 have been approved by the Board of Directors. The payment of the dividend shall be made on or after 12th June, 2023 to all the members of the Company whose names has been entered on Record Date i.e 7thJune, 2023.

30 May 2023

29 Aug 2022

AGM

29 Jul 2022

23 Aug 2022

Final Dividend (₹0.25)

Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2022, inter alia, has recommended final dividend @ Re. 0.25 (Rupee Zero and Paise Twenty Five) i.e. 25% per equity share of Re. 1/- each face value for the financial year ended March 31, 2022, subject to approval of the shareholders in the ensuing Annual General Meeting.

30 May 2022

15 Jul 2022

Buyback

Open Market Purchase - Max Price: ₹60, Amount: ₹60Cr

08 Jul 2022

23 Sept 2021

AGM

11 Aug 2021

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
277	12,546	30	4	24	0	14.59%
1,939	4,65,195	37	6	30	0	19.78%
6,811	1,80,823	69	11	59	0	23.41%
4,897	1,65,725	76	20	50	1	11.09%
1,442	1,16,467	31	3	23	0	9.92%
1,160	1,15,695	21	4	17	0	19.86%
2,503	1,14,441	20	5	16	0	14.56%
1,270	1,05,987	26	3	17	0	12.34%
2,531	1,04,544	52	6	36	0	14.39%
1,587	92,144	26	2	17	0	10.98%

Showing 10 of 134 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in less than 10 mins*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

DIXONDixon Technologies (India) Ltd
₹13,421-56 (-0.42%)

Frequently Asked Questions

What is Share Price of Marksans Pharma Ltd?

The current share price of Marksans Pharma Ltd (Marksans Pharma) is ₹272.40. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Marksans Pharma Ltd?

The Price-to-Earnings (P/E) ratio of Marksans Pharma Ltd is 272.40. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Marksans Pharma Ltd?

Marksans Pharma Ltd has a 52-week high of ₹281.60 and a 52-week low of ₹155.00. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Marksans Pharma Ltd?

Marksans Pharma Ltd offers a dividend yield of 0.32%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Marksans Pharma Ltd?

The Earnings Per Share (EPS) of Marksans Pharma Ltd is ₹9.22. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Marksans Pharma Ltd?

Marksans Pharma Ltd has a Return on Equity (ROE) of 14.45%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds. Play Video